Fast-track access to urologic care for patients with macroscopic haematuria is efficient and cost-effective: results from a prospective intervention study
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Fast-track access to urologic care for patients with macroscopic haematuria is efficient and cost-effective : results from a prospective intervention study. / Liedberg, Fredrik; Gerdtham, Ulf; Gralén, Katarina; Gudjonsson, Sigurdur; Jahnson, Staffan; Johansson, Irene; Hagberg, Oskar; Larsson, Staffan; Lind, Anna-Karin; Löfgren, Annica; Wanegård, Jenny; Åberg, Hanna; Nilbert, Mef.
In: B J C, Vol. 115, No. 7, 27.09.2016, p. 770-775.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Fast-track access to urologic care for patients with macroscopic haematuria is efficient and cost-effective
T2 - results from a prospective intervention study
AU - Liedberg, Fredrik
AU - Gerdtham, Ulf
AU - Gralén, Katarina
AU - Gudjonsson, Sigurdur
AU - Jahnson, Staffan
AU - Johansson, Irene
AU - Hagberg, Oskar
AU - Larsson, Staffan
AU - Lind, Anna-Karin
AU - Löfgren, Annica
AU - Wanegård, Jenny
AU - Åberg, Hanna
AU - Nilbert, Mef
PY - 2016/9/27
Y1 - 2016/9/27
N2 - BACKGROUND: The delay between onset of macroscopic haematuria and diagnosis of bladder cancer is often long.METHODS: We evaluated timely diagnosis and health-care costs for patients with macroscopic haematuria given fast-track access to diagnostics. During a 15-month period, a telephone hotline for fast-track diagnostics was provided in nine Swedish municipalities for patients aged ⩾50 years with macroscopic haematuria. The control group comprised 101 patients diagnosed with bladder cancer in the same catchment area with macroscopic haematuria who underwent regular diagnostic process.RESULTS: In all 275 patients who called 'the Red Phone' hotline were investigated, and 47 of them (17%) were diagnosed with cancer and 36 of those had bladder cancer. Median time from patient-reported haematuria to diagnosis was 29 (interquartile range (IQR) 14-104) days and 50 (IQR 27-165) days in the intervention and the control group, respectively (P=0.03). The median health-care costs were lower in the intervention group (655 (IQR 655-655) EUR) than in the control group (767 (IQR 490-1096) EUR) (P=0.002).CONCLUSIONS: Direct access to urologic expertise and fast-track diagnostics is motivated for patients with macroscopic haematuria to reduce diagnostic intervals and lower health-care expenditures.
AB - BACKGROUND: The delay between onset of macroscopic haematuria and diagnosis of bladder cancer is often long.METHODS: We evaluated timely diagnosis and health-care costs for patients with macroscopic haematuria given fast-track access to diagnostics. During a 15-month period, a telephone hotline for fast-track diagnostics was provided in nine Swedish municipalities for patients aged ⩾50 years with macroscopic haematuria. The control group comprised 101 patients diagnosed with bladder cancer in the same catchment area with macroscopic haematuria who underwent regular diagnostic process.RESULTS: In all 275 patients who called 'the Red Phone' hotline were investigated, and 47 of them (17%) were diagnosed with cancer and 36 of those had bladder cancer. Median time from patient-reported haematuria to diagnosis was 29 (interquartile range (IQR) 14-104) days and 50 (IQR 27-165) days in the intervention and the control group, respectively (P=0.03). The median health-care costs were lower in the intervention group (655 (IQR 655-655) EUR) than in the control group (767 (IQR 490-1096) EUR) (P=0.002).CONCLUSIONS: Direct access to urologic expertise and fast-track diagnostics is motivated for patients with macroscopic haematuria to reduce diagnostic intervals and lower health-care expenditures.
U2 - 10.1038/bjc.2016.265
DO - 10.1038/bjc.2016.265
M3 - Journal article
C2 - 27560554
VL - 115
SP - 770
EP - 775
JO - The British journal of cancer. Supplement
JF - The British journal of cancer. Supplement
SN - 0007-0920
IS - 7
ER -
ID: 173987040